UroGen Pharma Ltd.
URGN evidence brief
What we can confirm
- BioSniper Score:
- 5.1 / 10
- Market Cap:
- $2.20B
- Lead Asset:
- jelmyto (Approved)
What it means
What to watch
Prepared research question
What matters most for URGN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · URGN
UroGen Pharma Ltd. is a biotechnology company focused on developing and commercializing hydrogel-based therapies for urothelial cancers, with FDA-approved products Jelmyto and Zusduri and a pipeline including UGN-103 and UGN-301.
Key risk: Negative equity and losses
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 7 pipeline candidates · 7 clinical trials · 1 catalyst · 2 FDA decisions for UroGen Pharma Ltd..
UroGen Pharma Ltd. is a biotechnology company focused on developing and commercializing hydrogel-based therapies for urothelial cancers, with FDA-approved products Jelmyto and Zusduri and a pipeline including UGN-103 and UGN-301.
- Zusduri (mitomycin for intravesical solution) was FDA-approved in June 2025 and launched, achieving net sales of $15.8 million in 2025 [sec · filed 2026-04-30].
- UGN-103, a next-generation mitomycin formulation, completed Phase 3 UTOPIA trial enrollment with 99 patients and reported a 94.5% six-month duration of response [news · published 2026-05-18].
- Cash and equivalents were $79.1M as of 2026-06-30, with management stating sufficient cash to fund operations beyond one year [sec_mda · as of 2026-08-05].
- Shareholders' equity was -$132.4M as of 2026-06-30, reflecting accumulated losses [latest reported financials].
- A new U.S. patent covering non-TURBT treatment methods for low-grade NMIBC was granted, expected to provide protection into July 2044 [sec_mda · as of 2026-08-05].
What works
- Zusduri is the first and only FDA-approved medicine for recurrent low-grade intermediate-risk NMIBC, providing a unique market position [sec · filed 2026-04-30].
- UGN-103 showed a 94.5% six-month duration of response in the Phase 3 UTOPIA trial, indicating strong efficacy [news · published 2026-05-18].
- The company has a proprietary RTGel hydrogel technology platform that can improve therapeutic profiles of existing drugs [sec_mda · as of 2026-08-05].
- A new patent protecting non-surgical treatment methods strengthens intellectual property for Zusduri and UGN-103 through 2044 [sec_mda · as of 2026-08-05].
What to weigh
- The company has negative shareholders' equity of -$132.4M as of 2026-06-30, indicating accumulated losses exceed equity [latest reported financials].
- Net income was -$14.4M as of 2026-06-30, reflecting ongoing operating losses [latest reported financials].
- The company expects to continue incurring losses and negative net cash flows from operating activities [sec_mda · as of 2026-05-06].
- If product sales are insufficient, the company may need to raise additional capital, with no assurance of securing financing [sec_mda · as of 2026-08-05].
From the filings
Quoted directly from source documents.
UGN-103 achieved 94.5% six-month duration of response in Phase 3 UTOPIA trial.
“UGN - 103 achieved a 94.5% durability of...”
News · May 18, 2026
Catalyst timeline
- 2031-01-20 · Patent_Expiry · MITOMYCIN — Patent_Expiry: NDA215793 — The patent for mitomycin (NDA215793) expires, which could affect exclusivity for products like Zusduri and Jelmyto.
Risks & what to watch (3)›
Key risks
- Negative equity and losses — Shareholders' equity -$132.4M and net income -$14.4M as of 2026-06-30 [latest reported financials].
- Cash runway dependency — If product sales insufficient, may need to raise capital; no assurance of financing [sec_mda · as of 2026-08-05].
- Patent expiry risk — Patent for mitomycin (NDA215793) expires 2031-01-20, potentially affecting exclusivity [catalyst].
What to watch
- Zusduri sales trajectory and J Code reimbursement impact starting January 1, 2026 [sec · filed 2026-04-30].
- UGN-103 NDA progress and potential approval decision [news · published 2026-09-09].
- Cash runway updates and any capital raising activities [sec_mda · as of 2026-08-05].
- Patent expiry for mitomycin on 2031-01-20 [catalyst].
Sources: Catalysts · News · Pipeline · SEC filings · SEC MD&A · Generated October 11, 2026 · How we verify sources →
Run UroGen Pharma Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available UroGen Pharma Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$14M
Lead: Approved
7 candidates
1 upcoming, next in ~1559d
0 buys · 5 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 22, 2026- % of float
- 15.2%
- Days to cover
- 9.3
- Shares short
- 7,236,438
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
URGN short interestGovernance
Frequently asked questions
What is the AI investment thesis for UroGen Pharma Ltd.?
UroGen Pharma Ltd. is a biotechnology company focused on developing and commercializing hydrogel-based therapies for urothelial cancers, with FDA-approved products Jelmyto and Zusduri and a pipeline including UGN-103 and UGN-301.
What is UroGen Pharma Ltd.'s lead drug candidate?
UroGen Pharma Ltd.'s most advanced tracked candidate is jelmyto (Approved) for Urothelial Carcinoma.
What is UroGen Pharma Ltd.'s next catalyst?
UroGen Pharma Ltd.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA215793" — expected January 20, 2031.
Who is the CEO of UroGen Pharma Ltd.?
Ms. Elizabeth A. Barrett is the chief executive officer of UroGen Pharma Ltd. (URGN).
Where is UroGen Pharma Ltd. headquartered?
UroGen Pharma Ltd. (URGN) is headquartered in Princeton, NJ, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.